CVRX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CV

Mkt Cap

$37.0M

Volume

332.92K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

CVRx Responds to Letter from Pointillist Family OfficeCVRx's Board of Directors responded to a public letter from Pointillist Family Office shareholder Jorey Chernett, acknowledging that the company's valuation does not fully capture its business potential. The Board affirmed confidence in Barostim's differentiated position as the only FDA-approved neuromodulation therapy for heart failure and committed to pursuing strategies to drive growth while managing expenses. The Board remains open to shareholder engagement.GlobeNewswire Inc. · Aug 25, 2026

CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover LossesBlock & Leviton is investigating CVRx, Inc., Papa John's International, and HubSpot for potential securities fraud. CVRx cut its revenue guidance citing sales force challenges and reimbursement issues, while HubSpot experienced a 25% share price decline. Investors who have suffered losses are encouraged to contact the firm.GlobeNewswire Inc. · Aug 10, 2026

CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution DisclosuresJohnson Fistel is investigating CVRx, Inc. for potential securities law violations following the company's August 6, 2026 revenue guidance cut from $63-67 million to $58-60 million. The downward revision was attributed to sales force execution challenges, high employee turnover, slower productivity ramps, and reimbursement issues with a major Medicare Advantage payer. CVRx also disclosed receiving a Department of Justice civil investigative demand regarding sales and marketing practices.GlobeNewswire Inc. · Aug 7, 2026

CVRx, Inc. Investigated by the Portnoy Law FirmThe Portnoy Law Firm has initiated a securities fraud investigation into CVRx, Inc. following significant stock declines. The company's stock plummeted 46.3% in April 2025 after reporting weak Q1 revenue of $12.3 million, with management citing early-stage sales representative development. Further declines occurred in May 2025 (38.8%) and February 2026 (13.0%) as the company repeatedly downwardly revised guidance and acknowledged more significant salesforce restructuring than initially disclosed.GlobeNewswire Inc. · Apr 9, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNXPomerantz LLP is investigating potential securities fraud claims on behalf of investors in Beta Bionics, CVRx, and Navan. Beta Bionics experienced a significant stock price decline of 37% following the announcement of slower-than-expected patient growth in Q4 2025, with new patient starts increasing 36% year-over-year compared to 68% in the prior quarter.GlobeNewswire Inc. · Feb 17, 2026

CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the FirmLaw firm Bragar Eagel & Squire is investigating CVRx Inc. for potential federal securities law violations following significant stock price declines. CVRx shares dropped 46.3% on April 8, 2025 after the company announced weaker-than-expected Q1 results and disclosed that 25% of territory managers were recently hired. A second decline of 38.8% occurred on May 9, 2025 when the company lowered full-year revenue guidance.GlobeNewswire Inc. · Jan 30, 2026

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with BarostimCVRx's Barostim device has demonstrated significant reductions in hospital visits and length of stay for heart failure patients, according to new real-world evidence presented at the THT 2025 conference and published in the Journal of Cardiac Failure.GlobeNewswire Inc. · Feb 12, 2025

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceCVRx, a medical device company, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company's Barostim System, which uses neuromodulation to improve heart failure symptoms, has received FDA approval and the CE Mark in the European Economic Area.GlobeNewswire Inc. · Dec 23, 2024

Masimo Surges 8.7%: Is This an Indication of Further Gains?Masimo's shares surged 8.7% after the company's newly elected Board of Directors, proposed by activist investor Quentin Koffey, won election to the two available Board seats. Investors view this as a positive development, expecting the new Board to be more responsive to shareholders.Benzinga · Sep 23, 2024

Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. is investigating potential securities law violations by Arhaus, Cardlytics, and CVRx. The investigations focus on issues related to financial reporting, CEO departures, and reimbursement changes.GlobeNewswire Inc. · Aug 27, 2024

CV

CVRXCVRx, Inc. Common Stock

CVRX

Pay with—

Available Balance0.00

Your PositionYou don't own any CVRX yet.

Related Tickers

Earnings